From the Departments of Nuclear Medicine and PET/CT, and.
Surgery, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Clin Nucl Med. 2019 May;44(5):e364-e366. doi: 10.1097/RLU.0000000000002521.
Ga-DOTANOC PET/CT is well documented in evaluation of well-differentiated neuroendocrine tumors and in other lesions with somatostatin receptor expression such as pheochromocytoma, paraganglioma, neuroblastoma, meningioma, and mesenchymal tumors causing oncogenic osteomalacia. Causes of interpretative pitfalls include prominent pancreatic uncinate process activity, inflammation, osteoblastic activity (degenerative bone disease/fracture/vertebral hemangioma), splenunculi/splenosis, and others. We present a case of extraskeletal paravertebral lesion detected in a known case of breast cancer with increased Ga-DOTANOC uptake later proved to be hemangioma. This is a novel finding and should be kept as a rare benign differential in evaluation of lesions with somatostatin receptor expression.
Ga-DOTANOC PET/CT 已在评估分化良好的神经内分泌肿瘤以及其他具有生长抑素受体表达的病变中得到充分证实，如嗜铬细胞瘤、副神经节瘤、神经母细胞瘤、脑膜瘤和导致骨肿瘤性佝偻病的间叶肿瘤。导致解释陷阱的原因包括胰腺钩突活动度增加、炎症、成骨活性（退行性骨病/骨折/椎体血管瘤）、脾动静脉瘘/脾组织异位和其他原因。我们报告了 1 例已知乳腺癌患者的椎旁骨外病变，Ga-DOTANOC 摄取增加，后来证实为血管瘤。这是一个新的发现，在评估具有生长抑素受体表达的病变时，应将其作为罕见的良性鉴别诊断保留。
